{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:06:06Z","timestamp":1790611566995,"version":"4.1.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,29]]},"DOI":"10.1093\/cid\/cix675","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T03:11:30Z","timestamp":1501211490000},"page":"2137-2143","source":"Crossref","is-referenced-by-count":57,"title":["Increasing Evidence of the Nephrotoxicity of Piperacillin\/Tazobactam and Vancomycin Combination Therapy\u2014What Is the Clinician to Do?"],"prefix":"10.1093","volume":"65","author":[{"given":"Richard R","family":"Watkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Deresinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,29]]},"reference":[{"key":"key\n\t\t\t\t20171129035820_CIT0001","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","year":"2017","journal-title":"Intensive Care Med"},{"key":"key\n\t\t\t\t20171129035820_CIT0002","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jama.2014.12923","article-title":"Prevalence of antimicrobial use in US acute care hospitals, May-September 2011","volume":"312","year":"2014","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171129035820_CIT0003","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000337487","article-title":"Acute kidney injury and mortality in hospitalized patients","volume":"35","year":"2012","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t20171129035820_CIT0004","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2215\/CJN.03681106","article-title":"Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes","volume":"2","author":"Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171129035820_CIT0005","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1097\/CCM.0b013e3181de0c60","article-title":"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies","volume":"38","year":"2010","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t20171129035820_CIT0006","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1592\/phco.23.5.643.32199","article-title":"Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity","volume":"23","year":"2003","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171129035820_CIT0007","first-page":"7","article-title":"Infection problems for the 1990\u2019s\u2014do we have an answer?","volume":"91","year":"1993","journal-title":"Scand J Infect Dis"},{"key":"key\n\t\t\t\t20171129035820_CIT0008","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","article-title":"Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review","volume":"68","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20171129035820_CIT0009","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/2042018816638223","article-title":"Review of vancomycin-induced renal toxicity: an update","volume":"7","year":"2016","journal-title":"Ther Adv Endocrinol Metab"},{"key":"key\n\t\t\t\t20171129035820_CIT0010","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171129035820_CIT0011","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171129035820_CIT0012","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Infectious Diseases Society of America","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171129035820_CIT0013","first-page":"126","article-title":"Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy","volume":"67","year":"2014","journal-title":"Can J Hosp Pharm"},{"key":"key\n\t\t\t\t20171129035820_CIT0014","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","article-title":"A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia","volume":"29","year":"2007","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171129035820_CIT0015","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171129035820_CIT0016","volume-title":"Zosyn (piperacillin-tazobactam) package insert","year":"2012"},{"key":"key\n\t\t\t\t20171129035820_CIT0017","first-page":"278","article-title":"Piperacillin-tazobactam induced interstitial nephritis, hepatitis and serum sickness-like illness","volume":"112","year":"2016","journal-title":"J Ark Med Soc"},{"key":"key\n\t\t\t\t20171129035820_CIT0018","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/j.1875-9114.1997.tb03690.x","article-title":"Suspected acute interstitial nephritis induced by piperacillin-tazobactam","volume":"17","year":"1997","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171129035820_CIT0019","article-title":"Retrospective evaluation of the incidence of vancomycin and\/or piperacillin-tazobactam induced acute renal failure [abstract 301]","volume":"12","year":"2011","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t20171129035820_CIT0020","first-page":"200","article-title":"Acute kidney injury in patients receiving concomitant vancomycin and piperacillin\/tazobactam [abstract 714]","volume":"39","year":"2011","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t20171129035820_CIT0021","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciw811","article-title":"Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam","volume":"64","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171129035820_CIT0022","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171129035820_CIT0023","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/phar.1851","article-title":"Is the combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis","volume":"36","year":"2016","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171129035820_CIT0024","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/cid\/ciw709","article-title":"Risk of acute kidney injury in patients on concomitant vncomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime","volume":"64","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171129035820_CIT0025","first-page":"e02089","article-title":"Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171129035820_CIT0026","doi-asserted-by":"crossref","first-page":"O384","DOI":"10.1111\/1469-0691.12410","article-title":"Acute renal failure associated with vancomycin and \u03b2-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime","volume":"20","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171129035820_CIT0027","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/phar.1428","article-title":"Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime","volume":"34","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171129035820_CIT0028","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0897190016628960","article-title":"Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin","volume":"30","year":"2017","journal-title":"J Pharm Pract"},{"key":"key\n\t\t\t\t20171129035820_CIT0029","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/phar.1738","article-title":"Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study","volume":"36","year":"2016","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171129035820_CIT0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/dkf087","article-title":"Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial","volume":"50","author":"Spanish PETHEMA Group","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171129035820_CIT0031","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/phar.1918","article-title":"Acute kidney injury in patients treated with IV beta-lactam\/beta-lactamase inhibitor combinations","volume":"37","year":"2017","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171129035820_CIT0032","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/phar.1442","article-title":"Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam","volume":"34","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171129035820_CIT0033","doi-asserted-by":"crossref","first-page":"e000635","DOI":"10.1136\/bmjopen-2011-000635","article-title":"Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial","volume":"2","author":"Procalcitonin And Survival Study (PASS) Group","year":"2012","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20171129035820_CIT0034","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1941874416665744","article-title":"Predictors of acute kidney injury in neurocritical care patients receiving continuous hypertonic saline","volume":"7","year":"2017","journal-title":"Neurohospitalist"},{"key":"key\n\t\t\t\t20171129035820_CIT0035","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1517\/14740338.2016.1142528","article-title":"Safety profiles of old and new antimicrobials for the treatment of MRSA infections","volume":"15","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"key\n\t\t\t\t20171129035820_CIT0036","doi-asserted-by":"crossref","first-page":"ofw010","DOI":"10.1093\/ofid\/ofw010","article-title":"Outcomes of older adults with sepsis at admission to an intensive care unit","volume":"3","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t20171129035820_CIT0037","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s40265-016-0610-3","article-title":"Daptomycin pharmacokinetics and pharmacodynamics in septic and critically Ill patients","volume":"76","year":"2016","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20171129035820_CIT0038","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.clinthera.2015.05.501","article-title":"Susceptibility profile of ceftolozane\/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals","volume":"37","year":"2015","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171129035820_CIT0039","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajic.2011.05.020","article-title":"International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004\u20132009","volume":"40","year":"2012","journal-title":"Am J Infect Control"},{"key":"key\n\t\t\t\t20171129035820_CIT0040","doi-asserted-by":"crossref","first-page":"e0153696","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171129035820_CIT0041","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1017\/ice.2016.292","article-title":"Clinical risk score for prediction of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in bloodstream isolates","volume":"38","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20171129035820_CIT0042","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/jac\/dkl097","article-title":"Impact of diversity of antibiotic use on the development of antimicrobial resistance","volume":"57","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171129035820_CIT0043","first-page":"1520404","article-title":"Persistent bacteremia from Pseudomonas aeruginosa with in vitro resistance to the novel antibiotics ceftolozane-tazobactam and ceftazidime-avibactam","volume":"2016","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"key\n\t\t\t\t20171129035820_CIT0044","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1128\/AAC.03579-14","article-title":"Efficacy of a ceftazidime-avibactam combination in a murine model of septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum \u03b2-lactamases","volume":"58","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171129035820_CIT0045","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0924-8579(10)70005-4","article-title":"Antibiotic heterogeneity","volume":"36","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171129035820_CIT0046","first-page":"e02432","article-title":"Nasal methicillin-resistant Staphylococcus aureus (MRSA) PCR testing reduces the duration of MRSA-targeted therapy in patients with suspected MRSA pneumonia","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171129035820_CIT0047","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1060028016673858","article-title":"Randomized controlled trial to determine the efficacy of early switch from vancomycin to vancomycin alternatives as a strategy to prevent nephrotoxicity in patients with multiple risk factors for adverse renal outcomes (STOP-NT)","volume":"51","year":"2017","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20171129035820_CIT0048","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/phar.1901","article-title":"Comparison of rates of nephrotoxicity associated with vancomycin in combination with piperacillin-tazobactam administered as an extended versus standard infusion","volume":"37","year":"2017","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171129035820_CIT0049","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ofid\/ofv133.06","article-title":"Acute kidney injury in patients on concomitant vancomycin and piperacillin\/tazobactam: are extended infusions to blame?","volume":"2","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t20171129035820_CIT0050","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1128\/AAC.03011-15","article-title":"Epidemiology of acute kidney injury among patients receiving concomitant vancomycin and piperacillin-tazobactam: opportunities for antimicrobial stewardship","volume":"60","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171129035820_CIT0051","doi-asserted-by":"crossref","first-page":"77","DOI":"10.12788\/jhm.2684","article-title":"Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: a retrospective cohort analysis","volume":"12","year":"2017","journal-title":"J Hosp Med"},{"key":"key\n\t\t\t\t20171129035820_CIT0052","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/sur.2015.104","article-title":"Top Guns: The \u201cMaverick\u201d and \u201cGoose\u201d of empiric therapy","volume":"17","year":"2016","journal-title":"Surg Infect (Larchmt)"},{"key":"key\n\t\t\t\t20171129035820_CIT0053","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.clinthera.2016.01.001","article-title":"Impact of an antimicrobial stewardship program on patient safety in veterans prescribed vancomycin","volume":"38","year":"2016","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171129035820_CIT0054","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s13104-015-1518-9","article-title":"Risk factors for kidney injury during vancomycin and piperacillin\/tazobactam administration, including increased odds of injury with combination therapy","volume":"8","year":"2015","journal-title":"BMC Res Notes"},{"key":"key\n\t\t\t\t20171129035820_CIT0055","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1128\/AAC.00388-15","article-title":"Nephrotoxicity comparison of two commercially available generic vancomycin products","volume":"59","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171129035820_CIT0056","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1177\/1060028015594190","article-title":"Late-occurring vancomycin-associated acute kidney injury in children receiving prolonged therapy","volume":"49","year":"2015","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20171129035820_CIT0057","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/phar.1423","article-title":"Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors","volume":"34","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171129035820_CIT0058","first-page":"332","article-title":"Does combination therapy with vancomycin and piperacillin-tazobactam increase the risk of nephrotoxicity versus vancomycin alone in pediatric patients?","volume":"21","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"key\n\t\t\t\t20171129035820_CIT0059","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijantimicag.2017.02.023","article-title":"Acute kidney injury risk associated with piperacillin\/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function","volume":"50","year":"2017","journal-title":"Int J Antimicrob Agents"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/65\/12\/2137\/21968027\/cix675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T18:33:38Z","timestamp":1750790018000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/65\/12\/2137\/4055978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,29]]},"references-count":59,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,7,29]]},"published-print":{"date-parts":[[2017,11,29]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix675","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12,15]]},"published":{"date-parts":[[2017,7,29]]}}}